Mustang Bio, Inc. (MBIO): Price and Financial Metrics


Mustang Bio, Inc. (MBIO): $0.68

0.02 (+2.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MBIO Stock Price Chart Interactive Chart >

Price chart for MBIO

MBIO Price/Volume Stats

Current price $0.68 52-week high $1.23
Prev. close $0.66 52-week low $0.32
Day low $0.65 Volume 173,112
Day high $0.69 Avg. volume 680,720
50-day MA $0.50 Dividend yield N/A
200-day MA $0.59 Market Cap 71.87M

Mustang Bio, Inc. (MBIO) Company Bio


Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.


MBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

MBIO Latest Social Stream


Loading social stream, please wait...

View Full MBIO Social Stream

Latest MBIO News From Around the Web

Below are the latest news stories about MUSTANG BIO INC that investors may wish to consider to help them evaluate MBIO as an investment opportunity.

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced recent CAR T cell therapy p

Yahoo | December 19, 2022

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2022. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said,

Yahoo | November 14, 2022

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that results from the Waldenstrom macrogl

Yahoo | October 27, 2022

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q 2022 Ongoing clinical trial of MB-106 at Fred Hutch continues to demonstrate high efficacy, durable responses, and favorable safety profile across wide range of hematologic malignancies WORCESTER, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and ge

Yahoo | October 6, 2022

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City. Details of the events are as follows:

Yahoo | September 8, 2022

Read More 'MBIO' Stories Here

MBIO Price Returns

1-mo 72.20%
3-mo 25.93%
6-mo -9.32%
1-year -42.37%
3-year -81.47%
5-year -94.25%
YTD 72.20%
2022 -76.21%
2021 -56.14%
2020 -7.23%
2019 38.78%
2018 -75.48%

Continue Researching MBIO

Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:

Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7302 seconds.